KEYTRUDA® (pembrolizumab) KEYNOTE-826 clinical data presentation
Prescribing Information [External link]
The KEYNOTE-826 study explores KEYTRUDA
(pembrolizumab) in combination with chemotherapy with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥ 1
CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1
More information about KEYTRUDA® (pembrolizumab) in cervical cancer
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
